Drug therapy for benign prostatic hyperplasia. Systematic overview;Medikamentöse BPS-therapie. Eine systematische übersicht

Urologe - Ausgabe A

Volumn 44, Issue 5, 2005, Pages 505-512

  Berges, R ^a,c   Hofner K ^b  

^a Urologie   (Germany)

^b NONE

^c PAN Klinik am Neumarkt   (Germany)

Author keywords

1 Receptor blockers; 5 Reductase inhibitors; Benign prostatic hyperplasia; Combination therapy

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER PREVENTION; DRUG EFFICACY; HUMAN; MONOTHERAPY; ORGAN SIZE; PALLIATIVE THERAPY; PATIENT SELECTION; PROSTATE HYPERTROPHY; PROSTATE VOLUME; REVIEW; TREATMENT OUTCOME; UROLOGY;

ADRENERGIC ALPHA-ANTAGONISTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENZYME INHIBITORS; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; RISK ASSESSMENT; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME;

EID: 20044395802     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-005-0798-4     Document Type: Review

References (27)

1. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44: 461-466
2. Berges RR, Pientka L, Hofner K, Senge T, Jonas U (2001) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 39: 682-687
3. Berges RR, Michel MC, Jonas U (2002) Alpha 1-receptor blockade in therapy of benign prostatic hyperplasia syndrome. Correct dosing for optimal effectiveness. Urologe A 41: 452-457
4. Berges R, Dreikorn K, Hofner K et al. (2003) Guidelines of German urologists on therapy of benign prostate syndrome. Urologe A 42: 722-738
5. Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48: 398-405
6. Bruskewitz R, Girman CJ, Fowler J et al. (1999) Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 54: 670-678
7. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S (2004) Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 89: 2179-2184
8. Debruyne FM, Jardin A, Colloi D et al. (1998) Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 34: 169-175
9. Djavan B, Chapple C, Milani S, Marberger M (2004) State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64: 1081-1088
10. Dreikorn K, Berges R, Pientka L, Jonas U (2002) Phytotherapy of benign prostatic hyperplasia. Current evidence-based evaluation. Urologe A 41: 447-451
11. Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, Holmes SA (2000) A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 163: 496-498
12. Gomella LG (2005) Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol 15: 29-32
13. Kaplan S, Garvin D, Gilhooly P et al. (2000) Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. Urology 56: 610-616
14. Kaplan SA (2002) Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. J Urol 168: 1660
15. Kaplan SA (2005) Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. J Urol 173: 515
16. Kirby RS, Roehrborn C, Boyle P et al. (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61: 119-126
17. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46: 547-554
18. McConnell JD, Roehrborn CG, Bautista OM et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387-2398
19. McNeill SA, Hargreave TB, Roehrborn CG (2005) Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 65: 83-90
20. Michel MC (2005) The pharmacokinetic profile of tamsulosin oral controlled absorbtion system (OCAS). Eur Urol [Suppl] 4: 15-24
21. Miller MI, Puchner PJ (1998) Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 51: 237-240
22. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60: 434-441
23. Roehrborn CG, Bruskewitz R, Nickel JC et al. (2004) Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 171: 1194-1198
24. Roehrborn CG, Marks LS, Fenter T et al. (2004) Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63: 709-715
25. Stoner E (1992) The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 147: 1298-1302
26. Tammela TL, Kontturi MJ (1995) Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. J Urol 154: 1466-1469
27. Thompson IM, Goodman PJ, Tangen CM et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224wwWaWww